Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (10)

2023

  1. Correction to: Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells (Cancers, (2019), 11, 12, (1984), 10.3390/cancers11121984)

    Cancers

2022

  1. Neuropilin-1 as a Potential Biomarker of Prognosis and Invasive-Related Parameters in Liver and Colorectal Cancer: A Systematic Review and Meta-Analysis of Human Studies

    Cancers, Vol. 14, Núm. 14

2021

  1. Association of foxo3 expression with tumor pathogenesis, prognosis and clinicopathological features in hepatocellular carcinoma: A systematic review with meta-analysis

    Cancers, Vol. 13, Núm. 21

  2. Autophagy-related chemoprotection against sorafenib in human hepatocarcinoma: Role of foxo3 upregulation and modulation by regorafenib

    International Journal of Molecular Sciences, Vol. 22, Núm. 21

  3. Melatonin as an antitumor agent against liver cancer: An updated systematic review

    Antioxidants, Vol. 10, Núm. 1, pp. 1-27

2019

  1. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers

    Experimental and Molecular Medicine, Vol. 51, Núm. 9

  2. Antitumor effects of quercetin in hepatocarcinoma in vitro and in vivo models: A systematic review

    Nutrients, Vol. 11, Núm. 12

  3. Stabilization of hypoxia-inducible factors and BNIP3 promoter methylation contribute to acquired sorafenib resistance in human hepatocarcinoma cells

    Cancers, Vol. 11, Núm. 12

2018

  1. Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors

    Experimental and Molecular Medicine, Vol. 50, Núm. 10

2017

  1. Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxiamediated mitophagy

    Oncotarget, Vol. 8, Núm. 53, pp. 91402-91414